B 50 HabibE.Linher-MelvilleK.LinH.-X.SinghG
Common Medications Semaglutide (Wegovy and Ozempic for SQ injections, Rybelsus for PO) Liraglutide (Saxenda and Victoza for SQ injections) Tirzepatide (Mounjaro) Mechanism of Action GLP-1 is an incretin hormone produced in the small intestine, and it binds the GLP-1 receptor, thus enhancing the effects of endogenous GLP-1
Studies estimate that upper gastrointestinal bleeding affects approximately 50 to 100 people per 100,000 annually, with melena being one of the most recognisable symptoms
Preclinical and clinical data suggest that FXR and PPAR dual modulators can improve insulin sensitivity, reduce hepatic steatosis, and attenuate fibrosis, which may complement the actions of GLP-1/GIP/GCG receptors agonists
FDA-approved escalation for weight management (Wegovy protocol) *Exceeds standard 100-unit syringe capacity